T
ranscatheter aortic valve replacement (TAVR) has become a reasonable alternative to surgical aortic valve replacement for patients with severe symptomatic aortic stenosis who are at intermediate-to-high/ prohibitive surgical risk. [1] [2] [3] Although transfemoral access is considered the default access strategy, 10% to 15% of TAVR candidates do not have favorable iliofemoral anatomy for safe transfemoral access. 4 As experience with alternative access routes is growing, transcatheter heart valve (THV) technologies have evolved considerably over time, and important iterations have been implemented in many of the latest generation devices to diminish the proportion of patients deemed to be poor candidates for transfemoral access. 5 However, each access option has unique advantages and limitations that must be individualized to the patient's anatomy. 6 The carotid artery has been recently suggested as a feasible alternative access during TAVR, with encouraging short-and medium-term outcomes, harboring specific advantages over the more invasive transapical or transaortic strategies. [7] [8] [9] [10] [11] There are currently limited comparative data among the alternative TAVR approaches, and, therefore, we performed a multicenter comparison between transcarotid and transapical/transaortic approaches with respect to safety and early clinical outcomes.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results because of restrictions imposed by the patient consent process.
Patient Population
This prospective multicenter, observational registry was developed following the collaboration of the interventional cardiology and cardiac surgery departments across 3 tertiarycare hospitals from Canada and France. We identified 329 consecutive TAVR patients who underwent alternative nontransfemoral approaches including transapical, transaortic, or transcarotid, between January 2012 and June 2017. A transapical or transaortic TAVR was performed in 228 cases (159 transapical and 69 transaortic), whereas the transcarotid approach was used in 101 cases. To adjust for potential differences in patient perioperative risk, patients in the combined transapical/transaortic TAVR group were matched to patients in the transcarotid TAVR group using a propensity score analysis, as described in the statistical analysis section. The matched final study population consisted of 163 patients receiving transapical/transaortic TAVR and 94 patients receiving transcarotid TAVR.
At each participating institution, patients with severe aortic stenosis considered by the local multidisciplinary heart team to be at high or prohibitive surgical risk were considered for TAVR. Multimodality vascular evaluation was performed in all cases to select the optimal vascular access. Whenever feasible, transfemoral was considered as the first-line approach. Patients with unfavorable iliofemoral anatomy (minimal lumen diameter, ≤6 mm; severe calcification/tortuosity), significant disease of the thoracoabdominal aorta, or prior peripheral arterial interventions were not considered eligible for a transfemoral approach. Selection of alternative access was then individualized to each patient's anatomic features and comorbidities. However, transcarotid access was the favored approach during the latter part of the study period, if feasible, as described below. Transapical and transaortic were reserved for patients who were not considered candidates for a transcarotid approach, with selection between transapical and transaortic largely based on anatomy and comorbidity (previous cardiac surgery, severely calcified ascending aorta, left ventricular dysfunction with or without calcified apical aneurysm, severe chronic lung disease, etc). The yearly proportion of total TAVR cases that were not transfemoral TAVR in the 3 participating centers, from January 2012 to June 2017 was 18.4%, 20.1%, 16.7%, 15.4%, 20.9%, and 14.6% (Appendix in the Data Supplement; Figure I in the Data Supplement). The study was approved by the institutional review board of each participating institution. All patients gave written informed consent for participation in the registry, and this study met the requirements of each participating institutional review board.
Preprocedural Screening
All patients referred for TAVR underwent cardiac catheterization (followed by percutaneous revascularization if severe stenosis or functionally significant intermediate coronary stenosis was detected), as well as cardiac and global vascular assessment with multislice computed tomography (CT) studies. Aortic annulus area and perimeter, Valsalva sinus size, Agatston calcium score, and distance between the aortic valve annulus and coronary arteries were measured from CT studies, which informed the decision on the appropriate size and prosthesis type. In patients not suitable for a transfemoral approach, the carotid arteries were assessed by Doppler ultrasound and multislice CT evaluation of carotid and supra-aortic arch vessels to detect any functionally significant stenosis or flow disturbance. Transcarotid access was considered feasible when the 2 following criteria were satisfied: (1) 
Procedural Technique
In all cases, TAVR was performed under general anesthesia, with invasive hemodynamic monitoring and continuous cerebral saturation assessment with the INVOS system (Medtronic, Minneapolis, MN). Additional simultaneous electroencephalogram monitoring was used in 2 of the 3 centers. 12 Radial or femoral arterial access was used for pigtail guidance to the plane of the aortic valve, and a temporary pacemaker was implanted either by jugular or femoral vein access. Fluoroscopic and transesophageal echocardiography guidance were performed, with unfractionated intravenous heparin given to achieve an activated clotting time of ≥250 seconds. All patients were receiving at least single-antiplatelet therapy at the time of TAVR.
Transcarotid TAVR was performed following a previously published technique. 13 To summarize, an intraprocedural indirect evaluation of the functional integrity of the arterial circle of Willis and patency of the contralateral CCA were performed in 1 of the 3 centers. For this purpose, the proximal CCA was clamped during a 2-minute period during which time the distal arterial pressure and cerebral oximetry were measured. A decrease of the mean backflow pressure to <30 mm Hg or a decrease of ≥50% in cerebral saturation during the clamp test that did not respond to moderate hemodynamic support was considered an indication to perform a temporary femorocarotid external shunt. If these criteria were not met, no carotid bypass shunt was indicated. In this series, these criteria were not met in all patients in whom the test was performed no carotid shunt was implanted. The choice of valve type, balloon valvuloplasty, and post-dilatation was left to the discretion of the operator.
Clinical End Points and Definitions
The outcomes of interest in this study included periprocedural and 30-day all-cause mortality, stroke, device success, early safety, and major outcomes according to the Valve Academic Research Consortium-2 consensus definitions.
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Statistical Analysis
A continuous propensity score analysis was performed to adjust for the intergroup clinical differences. A propensity score representing the likelihood of having a transcarotid was calculated for each patient by the use of multivariable logistic regression analysis that identified variables independently associated with transcarotid. Continuous variables were checked for the assumption of linearity in the logit and the graphical representations suggested linear relationships. Interactions between variables were allowed only if it was supported clinically and statistically (P<0.20). Variables retained in the final model were age, hypertension, history of stroke or transient ischemic attack (TIA), history of myocardial infarction, peripheral vascular disease, and the following 2 interaction terms: age and peripheral vascular disease, age and hypertension. The goodness-of-fit of the model using the Hosmer-Lemeshow test indicated that the final model was a good fit (χ 2 =4.52 with df=8; P=0.81). Matching was then performed on the propensity score without replacement of case and control subjects (many to many or complete matching) using the greedy algorithm. A detailed description of the matching algorithm is available in the Appendix in the Data Supplement. This complete matching algorithm allows for maximal use of patients by minimizing exclusion of outliers. Using this procedure, 94 of 101 transcarotid patients (93.1%) were matched to 163 transapical/transaortic patients, creating a series of 58 matched sets with no limitation of the ratio of transcarotid to control patients. After full matching, statistical analyses used a weighted approach, taking into account the clustering of patients within each stratum of match. In addition, a second propensity score model was fit forcing institution into the model to assess for a potential confounding effect by center. Continuous variables are expressed as weighted mean±SD and analyzed using the linear regression model adjusted for stratification (blocking factor). Categorical variables are expressed using proportions and analyzed with a linear model and a logit link function adjusted for stratification (blocking factor). Statistical significance was present when the 2-tailed P value was <0.05. Analyses were performed using SAS, version 9.4 (SAS Institute, Inc, Cary, NC).
RESULTS
Baseline clinical and echocardiographic data comparing unmatched and propensity score-matched transcarotid compared with transapical/transaortic patients are shown in Table 1 Initially, 104 patients had been selected for transcarotid access. In 3 of these patients, the transcarotid approach was abandoned after CCA exposure. Two cases were because of extensive calcification of the CCA when assessed by the surgeon on palpation before the puncture, which was not evident on preprocedural imaging. The other case was because of a low CCA bifurcation precluding safe access to the vessel. These 3 patients all underwent successful transaortic TAVR at the same sitting. Therefore, successful vascular access was achieved in all patients in the transapical/transaortic group and in 101 (97.1%) patients in the transcarotid group. Procedural characteristics are summarized in Table 2 . Most patients (89.4%) in the transapical/transaortic group received the Edwards SAPIEN, SAPIEN XT, or SAPIEN 3 THV (Edwards Lifesciences, Irvine, CA). In the transcarotid group, the SAPIEN family of valves was implanted in 58 patients (57.4%) and the Medtronic CoreValve and Evolut R THV (Medtronic, Minneapolis, MN) in 43 patients (42.6%).
After adjustment, there were no significant betweengroup differences on access site infection (n=1 in the transapical approach), cardiac tamponade, and procedural mortality (0% versus 2.1%; P=0.16; transcarotid versus transapical/transaortic, respectively). In addition, there was no need to implant a second valve or convert to sternotomy in the transcarotid group. Postimplantation hemodynamics demonstrated a significant reduction in transvalvular aortic mean gradient and an increase in the effective orifice area in both groups ( Figure) .
Postprocedural and 30-day clinical outcomes were available in all patients surviving the procedure (Table 3) . At 30 days, there were 3 cases (2.9%) of Valve Academic Research Consortium-2-defined strokes (2 disabling fatal and 1 nondisabling) in the transcarotid group. These patients underwent CT or magnetic resonance imaging and were assessed by a consultant neurologist. Two strokes were noted in the immediate postoperative period and 1 on postoperative day 6. This patient had preoperative atrial fibrillation treated with oral anticoagulation and had a hemorrhagic stroke contralateral to the transcarotid access site. The other 2 patients had ischemic strokes ipsilateral to the accessed CCA. However, the risk of stroke/TIA was not significantly different between the matched transcarotid versus transapical/transaortic groups (2.1% versus 3.5%; P=0.67). All patients were prescribed antiplatelet therapy before the procedure and received therapeutic intraprocedural heparin.
Compared with transapical/transaortic TAVR, transcarotid TAVR was also associated with significantly less new-onset atrial fibrillation ( less major vascular complications with the transcarotid approach (3.2% versus 10.7%; P=0.05). At 30 days, mortality rate in the matched cohort was 2× higher in the transapical/transaortic compared with transcarotid group, although this difference did not reach statistical significance (4.6% versus 2.1%; P=0.37, respectively).
There was a greater proportion of the newer iterations of THV in the transcarotid group. Therefore, we reevaluated outcomes after adjusting for prosthesis type to mitigate a possible confounding effect related to enhanced features of the newer THV, such as lower profile delivery systems. The significant salutary effect of transcarotid access on postprocedural atrial fibrillation persisted, despite adjusting for THV type. However, the association between transcarotid access and major or life-threatening bleeding became nonsignificant, as was the association between THV type and bleeding. Taken together, these data suggest that, although THV type may be partly responsible for the decreased risk of bleeding associated with transcarotid access, it does not entirely explain this protective effect (prosthesisadjusted analysis, Appendix in the Data Supplement).
No major differences in clinical outcomes were observed by comparing transapical to transaortic, except for the risk of acute kidney injury that was higher among transaortic patients (23.2% versus 11.3%; P=0.03; unadjusted data; Appendix in the Data Supplement; Tables IV through VI in the Data Supplement). Institution-specific outcomes for the entire cohort of transcarotid patients were also compared, and no major differences were observed (Appendix in the Data Supplement; Table VII in the Data Supplement). When institution was forced into the propensity score model to adjust for a potential confounding effect by center, we obtained similar results to the main analysis (Appendix in the Data Supplement; Table VIII in the Data Supplement).
DISCUSSION
This is the first report of a multicenter propensity scorematched comparison between transcarotid and transthoracic access. The main findings are (1) transcarotid TAVR is safe and feasible in appropriately selected patients with a high rate of device success (87%); (2) compared with transapical and transaortic TAVR, the transcarotid approach was associated with no significant difference in rates of 30-day all-cause mortality, stroke, new pacemaker implantation, major vascular complications, and hemodynamic performance; (3) transcarotid TAVR is associated with significantly less new-onset atrial fibrillation, acute kidney injury, major or life-threatening bleeding, and shorter hospital stay.
TAVR technology has evolved considerably in the last few years allowing for the treatment of 85% to 90% of patients via the transfemoral route. 4, 15, 16 Until recently, the transapical and transaortic approaches were considered the main alternative nontransfemoral routes, with comparable short-and long-term outcomes. [17] [18] [19] Despite their advantage of simplifying valve positioning, major surgical manipulation of the chest wall is required. Furthermore, these techniques are limited by relative contraindications, such as significant respiratory failure in case of transapical, and porcelain aorta, as well as previous heart surgery, in cases of transaortic. Transcarotid TAVR was first performed in France in 2009, 20 and then was subsequently adopted by several other centers. [7] [8] [9] 21, 22 These experiences demonstrated that the surgical approach to the carotid artery is safe and relatively uncomplicated because of its superficial location, and operative experience with the carotid arteries is widespread among cardiovascular surgeons. We prefer performing transcarotid TAVR using the left Values are expressed as percentage, n (%), or mean ±SD. LOS indicates length of stay; TA, transapical; TAo, transaortic; TC, transcarotid; and TIA, transient ischemic attack.
*The estimates obtained after propensity score matching are based on the means of a stratified sampling of weighted subjects. More details are provided in Appendix in the Data Supplement.
common carotid because it allows superior coaxial alignment of the THV with the aortic annulus, although both sides can be used. 9, 10, 21 In the current study, the 30-day crude stroke or TIA rate in the transcarotid group was 3% (2 disabling and 1 nondisabling stroke), with no significant difference compared with the transapical/transaortic group (as previously described in smaller studies). 10, 11 This stroke rate is lower than that observed in the cohort of patients included in the multicenter French Transcarotid TAVR Registry and others. 8, 9 As previously described, 8, 21 these neurological events are not always localized ipsilateral to the CCA used for TAVR. This suggests that there are other phenomena at play in addition to carotid arterial manipulation, such as new-onset postprocedural atrial fibrillation, periprocedural hypotension, inadequate contralateral carotid perfusion, and the THV deployment itself. Although the rates of preimplant and postimplant balloon valvuloplasty were significantly higher in the transapical/transaortic group even after adjustment, this did not translate to a higher risk of stroke or TIA among the transapical/transaortic patients. The low rate of stroke observed in this study may be attributed to careful patient selection and the intraoperative assessment of the functional integrity of the circle of Willis as used in one center in this study, using indirect methods, such as backflow blood pressure during carotid clamping and cerebral oximetry monitoring. 7 However, the optimal preprocedural evaluation and periprocedural neurological monitoring during transcarotid TAVR are yet to be determined. Also, the optimal antithrombotic regimen and the role of embolic protection devices [23] [24] [25] require further study to determine efficacy in the reduction of the risk of cerebral ischemia, specifically in patients undergoing transcarotid TAVR as literature is scarce in these patients.
Other major findings of this study were that transcarotid TAVR was significantly associated with a reduction in major or life-threatening bleeding and shorter LOS, compared with transapical/transaortic TAVR. This could be explained by (1) less-invasive access site exposure in the case of transcarotid TAVR compared with a minithoracotomy or hemisternotomy in the transapical/transaortic approach; (2) less ventilator use and shorter intensive care unit stay in transcarotid TAVR 10 ; and (3) less pain during the postprocedural recovery and earlier patient mobilization. The lower incidence of new-onset atrial fibrillation among transcarotid TAVR patients may also partly explain shorter LOS. Any incision of the thoracic cavity is associated with various forms of supraventricular arrhythmia, most commonly atrial fibrillation, which may then translate to a prolonged hospital stay. 26, 27 A reduction of LOS is a critical component of current strategies to control overall costs associated with TAVR and may be the primary driver of reduced expenditure associated with transfemoral TAVR compared with alternative-access TAVR. [28] [29] [30] Furthermore, severe bleeding may be associated with postprocedural hypovolemia and may explain, in part, the reduction in the rates of severe acute kidney injury in transcarotid cases compared with the transapical/ transaortic approach. 31, 32 Similar findings were previously reported when comparing transapical or transaortic with transfemoral access. Blackstone et al 33 reported their results in 501 propensity score-matched patients undergoing transapical versus transfemoral TAVR. More patients in the transapical group experienced adverse procedural events, longer length of stay, slower recovery, and higher transfusion rates. Similar results were published by Arai et al, 34 who reported significantly higher rates of life-threatening bleeding when comparing transaortic (n=289) with transfemoral TAVR (n=467; 6% versus 3%, respectively; P=0.021) without a significant difference in other major outcomes. Our data also suggest that the risk of major vascular complications are decreased with a transcarotid TAVR approach (matched analysis, 3.2% versus 10.7%; P=0.05), although the study was underpowered for this specific end point and did not reach statistical significance.
Postoperative echocardiographic data showed favorable results in both groups, as either access provides direct aortic annular access and may allow superior positioning in particular anatomies (Figure) . The observed 30-day mortality in the adjusted analysis (2.1% versus 4.6%; P=0.37; transcarotid versus transapical/transaortic, respectively) was also statistically comparable between groups and lower than that previously reported in transcarotid TAVR cohorts. 8, 9 
Study Limitations
This report consists of a retrospective analysis of prospectively acquired data and is subject to the limitations inherent in this study design. Selection of patients was not random and may not be generalizable to other centers. Other alternative approaches, such as the subclavian route, were not evaluated because of the limited number of patients undergoing TAVR by subclavian access at the participating centers. The superficial position of the carotid artery coupled with the more complex exposure of the subclavian and its proximity to the brachial plexus, and the risks associated with its use if an ipsilateral internal mammary artery was used as a coronary bypass graft, have lead us to favor transcarotid over the subclavian approach. As well, specific end points, such as mortality, stroke, and major vascular complications, may have not reached statistical significance because of the small sample size and short-term follow-up. However, this is the largest multicenter study evaluating the transcarotid approach using a risk-adjusted comparator arm. Small numbers did not permit us to ascertain device-specific outcomes. However, adjusting the analysis for type of THV, we found that the association between decreased major bleeding and the transcarotid approach was modulated, in part, by the use of newer valve types with their lower profile delivery systems but was not entirely explained by this feature of the newer THVs (Appendix in the Data Supplement). Taken further, this association may also be access site specific and not entirely device specific. Accessing proximal highpressure structures, such the left ventricular apex and ascending aorta, may be associated with less ability to adequately control bleeding compared with distal arterial sites, such as the carotid artery. Device-specific features of the newer TAVR prostheses, such as improved sealing skirts, did not influence postprocedural aortic regurgitation, need for a permanent pacemaker, pressure gradients, and overall procedural success rates in our study, which were similar between the transcarotid and transapical/transaortic groups.
Periprocedural cerebral monitoring was variable among institutions during transcarotid TAVR, reflecting a lack of consensus in the literature, and the rates of neurological events may have been underestimated because systematic evaluation by magnetic resonance imaging was not routinely performed following TAVR. However, the incidence of stroke/TIA was low and did not differ among centers (Table VII in the Data Supplement); the optimal perioperative neuromonitoring technique remains to be prospectively elucidated. However, all clinically significant neurological changes were identified, and all sites had a low-threshold trigger for consultation by a neurologist and the performance of neuroimaging post-TAVR. Preprocedural and postprocedural antiplatelet and anticoagulation therapy were not consistently captured across the study centers, which may confound the association between the approaches studied and outcomes, such as bleeding, cerebrovascular events, and mortality. However, all centers stopped the second antiplatelet agent at least 48 hours before the procedure for patients undergoing transapical or transaortic TAVR. We, therefore, cannot attribute the increased bleeding rates associated with transapical/transaortic solely to preoperative double antiplatelet therapy.
Conclusions
Transcarotid vascular access for TAVR is safe, feasible, and associated with encouraging short-term clinical outcomes in terms of mortality, stroke, and major vascular complications in patients who are not candidates to transfemoral TAVR. Furthermore, the transcarotid approach was associated with lower rates of major or life-threatening bleeding, new-onset atrial fibrillation, acute kidney injury, and shorter LOS compared with transapical or transaortic access. Larger prospective studies with longer follow-up are needed to confirm
